General anesthetics

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Retrieved on: 
Thursday, June 3, 2021
Psychoactive drugs, Drugs, Neurochemistry, NMDA receptor antagonists, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, General anesthetics, Ketamine, Clinic

Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.

Key Points: 
  • Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.
  • The IRP team is excited to join Ketamine One and combine resources to grow its clinics across Canada.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Myconic Capital Becomes Ketamine One

Retrieved on: 
Tuesday, June 1, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).

Key Points: 
  • VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).
  • Ketamine Ones board of directors has appointed Dr. Mark Kimmins as the Companys Chief Medical Officer.
  • We are excited to reveal the re-brand of the Company to Ketamine One, which more accurately reflects our vision to quickly become a leader in the delivery of breakthrough mental wellbeing treatments, said Adam Deffett, VP of Capital Markets for Ketamine One.
  • KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused becoming a North American leader in mental health.

/R E P E A T -- Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants/

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, General anesthetics, NMDA receptor antagonists, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Esketamine, Mental disorder

"With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.

Key Points: 
  • "With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.
  • Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, General anesthetics, NMDA receptor antagonists, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Esketamine, Mental disorder

"With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.

Key Points: 
  • "With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.
  • Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

XWPharma Announces Abstract for XW10172 Accepted for Presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Sleep disorders, Glutamate, Neurochemistry, Psychoactive drugs, General anesthetics, Neurotransmitters, Amphetamine, Narcolepsy, gamma-Hydroxybutyric acid, Excessive daytime sleepiness, AMPA

The drug and formulation are designed to deliver oxybate without the sodium content of other products that is associated with increased cardiovascular health risk and monitoring requirements.

Key Points: 
  • The drug and formulation are designed to deliver oxybate without the sodium content of other products that is associated with increased cardiovascular health risk and monitoring requirements.
  • XWPharma's expertise in drug design is focused on providing potential first- and best-in-class medicines with differentiated features to address the unmet medical needs of patients suffering from debilitating neurological diseases.
  • XW10172 is a clinical-stage conjugate of the GABAB agonist, oxybate, in development as an investigational once-nightly therapy intended to regulate the patient\xe2\x80\x99s sleep cycle in order to alleviate excessive daytime sleepiness and other consequences of sleep dysfunction associated with neurodegenerative diseases, including Parkinson\xe2\x80\x99s disease and narcolepsy.
  • XW10508 is a glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy with potential abuse deterrent properties, designed for the treatment of major depressive disorder and chronic pain.\n"

Lamar Odom Reborn: New Documentary Follows NBA Athlete's Journey to Beat Addiction and Anxiety Through the Use of Psychedelic Medicines

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, Nicotinic antagonists, General anesthetics, Chloroarenes, Sedatives, Ketamine, Ibogaine, Odom, Post-traumatic stress disorder

Lamar admits he self-medicated and avoided professional interventions given the stigma attached with mental health treatment.\n"Admitting you are depressed or asking for help is a challenge for anyone," says Odom.

Key Points: 
  • Lamar admits he self-medicated and avoided professional interventions given the stigma attached with mental health treatment.\n"Admitting you are depressed or asking for help is a challenge for anyone," says Odom.
  • "My hope is that sharing my journey in Reborn will open a dialogue for millions of people.
  • Just months after my first ketamine and ibogaine treatments, I felt physically well enough to play professional basketball again.
  • "Ketamine, however, is an FDA-approved anesthetic that has been hailed as a miracle for treating depression, anxiety, PTSD, addiction, and more.

Delic's Acquisition Target, Ketamine Infusion Centers, Announces Proposal to Acquire 2 Additional Clinic Locations

Retrieved on: 
Tuesday, May 11, 2021
Psychoactive drugs, Drugs, Medical specialties, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Post-traumatic stress disorder, KIC

("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.

Key Points: 
  • ("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.
  • "KIC is the leading name in high quality care and incredible outcomes for its patients and this move helps grow that reputation significantly.
  • As a vital part of the Delic platform, KIC will continue to offer wellness and benefits for many people suffering from anxiety, depression and PTSD.
  • Ketamine Infusion Centers unique model and passion to obtain the highest patient outcomes and purely evidence-based practices is a perfect fit in the Delic ecosystem.

Global Neuroprotection Markets, Methods, Drugs, and Competitive Landscape Report 2021 with Profiles of 141 Companies & 126 Collaborations - ResearchAndMarkets.com

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Neurology, Clinical medicine, General anesthetics, Branches of biology, Neuroprotection, Anesthesia, Propofol, Anesthetic

Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.\nPathomechanisms of diseases are described with steps at which neuroprotective therapies are directed.

Key Points: 
  • Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.\nPathomechanisms of diseases are described with steps at which neuroprotective therapies are directed.
  • Although anesthetics such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating complications that result in CNS damage.\nThe report contains profiles of 141 companies that have a neuroprotective product or products along with 126 collaborations.
  • Some of the products in development at academic institutions that do not have a commercial sponsor are also included.
  • By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effectively.\n'

China Sevoflurane Investigation Markets, 2016-2020 & 2021-2025: Market to Have a Strong Recovery Post COVID-19

Retrieved on: 
Tuesday, May 4, 2021
GABAA receptor positive allosteric modulators, General anesthetics, NMDA receptor antagonists, Medical specialties, Neurochemistry, Ethers, Organofluorides, Chemistry, Sevoflurane, Anesthetic, Inhalational anesthetic, Anesthesia

b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Investigation Report on China\'s Sevoflurane Market, 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSevoflurane is an inhalation general anesthetic and also the main inhalation anesthetic at this stage.

Key Points: 
  • b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Investigation Report on China\'s Sevoflurane Market, 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSevoflurane is an inhalation general anesthetic and also the main inhalation anesthetic at this stage.
  • Inhaled Sevoflurane was originally developed by Abbott and entered the Chinese market in 1996.\nIn the Chinese market, with the prevalence of chronic diseases, the improvement of the medical system, and the intensification of aging in some regions, the number of operations has increased.
  • Moreover, due to the therapeutic advantages of Sevoflurane, it dominates the anesthesia market.
  • Therefore, the analyst predicts that the sales of Sevoflurane will increase in the future.\nAccording to the analyst\'s market research, the sales revenue of Sevoflurane in the Chinese market has increased from 2017 to 2019, and reached CNY729.39 million in 2019.

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

Retrieved on: 
Monday, May 3, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Ketamine, Forward-looking statement

The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.

Key Points: 
  • The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.
  • Our goal is to improve the access and quality of mental healthcare service to people affected by these disorders in a highly cost-effective manner.
  • All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements.
  • There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/champignon-brands-changes-name-t...\n'